Cataract surgery system in clinical trials

“Years in development, OptiMedica's Catalys Precision Laser System has been the subject of significant clinical study, and we are confident that the data unveiled at ESCRS will truly set us apart in this incredibly exciting therapeutic area,” was the view of Mark Forchette, OptiMedica president and CEO. Drs Batlle, Vukich and Koch, from OptiMedica’s Cataract Advisory Board, discussed the data during three presentations at the annual ESCRS in Paris this year.

The three cataract experts have been working closely with the company during the development of its Catalys Precision Laser system and together have treated hundreds of pre-clinical eyes.

The presentations explored the system’s ability to deliver a marked improvement at various critical points during the cataract procedure. Dr Batlle looked at Prospective Randomized Study of Size and Shape Accuracy of OptiMedica Femtosecond Laser Capsulotomy vs. Manual Capsulorrhexis, The Role of Precise Anterior Capsulotomies in Premium Lens Performance Objectives was presented by Dr John Vukich and The Use of OCT-guided Femtosecond Laser to Facilitate Cataract Nuclear Disassembly and Aspiration was Dr Koch.

These presentations follow on from the recent sale of the company’s retina and glaucoma business to Topcon, positioning it to focus exclusively on advanced technologies for the treatment of cataract.

Further details of these results will feature in an upcoming issue of Ophthalmology Times Europe.